肺癌精准治疗的发展与展望  

Perspective of Precision Therapy on Lung Cancer

作　　者：任胜祥[1] 邱天羽 REN Shengxiang;QIU Tianyu(Department of Oncology,Shanghai Pulmonary Hospital&Thoracic Cancer Institute,Tongji University School of Medicine,Shanghai 200433,China)

机构地区：[1]同济大学附属上海市肺科医院肿瘤科,上海200433

出　　处：《肿瘤防治研究》2023年第5期442-451,共10页Cancer Research on Prevention and Treatment

基　　金：上海市优秀学科带头人计划项目(21XD1423200)。

摘　　要：目前,肺癌仍然是我国发病率和死亡率较高的恶性肿瘤。传统放化疗疗效有限,肺癌治疗新药物和新方案的探索一直在进行中。过去20多年,随着分子靶向和免疫治疗的飞速发展,临床疗效不断刷新,越来越多的癌症患者从中获益。肺癌治疗方法日新月异,是实体肿瘤精准治疗领域的“排头兵”。本文梳理了肺癌精准靶向和免疫治疗的发展历程,并对存在的问题及未来发展方向进行探讨。Lung cancer remains to have the highest morbidity and mortality rates in China among known malignant tumors.Novel drugs and regimens have been sought because of the limited efficiency of traditional chemotherapy and radiotherapy in lung cancer treatment.In the last 20 years,rapid developments in molecular targeted therapy and immunotherapy have increased clinical efficacy and benefitted patients with cancer.Treatments for lung cancer are the most rapidly developed among treatments for solid tumors,pioneering tumor precision medicine.This manuscript reviews the evolution and development of targeted therapy and immunotherapy and discusses existing problems and future directions in the precision therapy of lung cancer.

关 键 词：肺癌 精准医疗 分子靶向治疗 免疫治疗 

分 类 号：R734.2[医药卫生—肿瘤]